Edition:
India

MediciNova Inc (MNOV.OQ)

MNOV.OQ on NASDAQ Stock Exchange Global Market

8.86USD
14 Dec 2018
Change (% chg)

$-0.29 (-3.17%)
Prev Close
$9.15
Open
$9.08
Day's High
$9.29
Day's Low
$8.84
Volume
70,344
Avg. Vol
24,771
52-wk High
$14.50
52-wk Low
$6.30

Latest Key Developments (Source: Significant Developments)

Medicinova Expects Loss Per Share Of $0.44 For Year Ending Dec 31
Friday, 26 Oct 2018 

Oct 26 (Reuters) - MediciNova Inc ::MEDICINOVA INC - EXPECTED BASIC AND DILUTED LOSS PER SHARE FOR YEAR ENDING DECEMBER 31, 2018 IS $0.44.  Full Article

Medicinova Announces Positive FDA Feedback Regarding Phase 3 Plan For MN-166
Wednesday, 26 Sep 2018 

Sept 25 (Reuters) - MediciNova Inc ::MEDICINOVA ANNOUNCES POSITIVE FDA FEEDBACK REGARDING PHASE 3 PLAN FOR MN-166 (IBUDILAST) IN ALS.MEDICINOVA -NO SAFETY ISSUES REGARDING MN-166 (IBUDILAST) WERE RAISED BY FDA AND SAFETY PROFILE WILL BE REVISITED ONCE PIVOTAL RESULTS ARE AVAILABLE.  Full Article

MediciNova to collaborate with UCLA researchers in grant-funded clinical trial of MN-166 (ibudilast) in alcohol use disorder and withdrawal
Tuesday, 8 May 2018 

May 8(Reuters) - MediciNova Inc :Says it plans to initiate a clinical trial of MN-166 (ibudilast) in alcohol dependence and withdrawal in collaboration with researchers at the University of California, Los Angeles (UCLA).  Full Article

MediciNova Posts Results Of Phase 2 Clinical Trial Of MN-166 In Methamphetamine Dependence
Thursday, 29 Mar 2018 

March 29 (Reuters) - MediciNova Inc ::MEDICINOVA ANNOUNCES RESULTS OF PHASE 2 CLINICAL TRIAL OF MN-166 (IBUDILAST) IN METHAMPHETAMINE DEPENDENCE.MEDICINOVA INC - ‍DID NOT MEET PRIMARY ENDPOINT OF METHAMPHETAMINE ABSTINENCE CONFIRMED VIA URINE DRUG SCREENS DURING FINAL TWO WEEKS OF TREATMENT​.MEDICINOVA INC - ‍MN-166 (IBUDILAST) DEMONSTRATED A FAVORABLE SAFETY AND TOLERABILITY PROFILE​.MEDICINOVA INC - ‍THERE WAS NOT AN INCREASED RATE OF SERIOUS OR SEVERE ADVERSE EVENTS IN MN-166 (IBUDILAST) GROUP COMPARED TO PLACEBO GROUP​.MEDICINOVA INC SAYS THERE WERE NO INFECTIONS, NO CANCERS, NO CARDIOVASCULAR EVENTS NO DEATHS RELATED TO MN-166.MEDICINOVA - COMMON TREATMENT-RELATED ADVERSE EVENTS DURING STUDY WERE GASTROINTESTINAL ADVERSE EVENTS, OCCURRED WITH HIGHER FREQUENCY IN MN-166 GROUP​.  Full Article

Medicinova Announces Positive Top-Line Results From Clinical Trial Of MN-166 (ibudilast) In ALS
Friday, 8 Dec 2017 

Dec 7 (Reuters) - Medicinova Inc ::MEDICINOVA ANNOUNCES POSITIVE TOP-LINE RESULTS FROM THE CLINICAL TRIAL OF MN-166 (IBUDILAST) IN ALS.MEDICINOVA INC - TRIAL ACHIEVED PRIMARY ENDPOINT OF SAFETY AND TOLERABILITY, AND ALSO DEMONSTRATED EFFICACY TRENDS IN FAVOR OF MN-166.MEDICINOVA INC - THERE WERE 7 SERIOUS ADVERSE EVENTS (SAES) REPORTED DURING STUDY BUT NONE OF SAES WERE RELATED TO STUDY DRUG.MEDICINOVA INC - MN-166 DEMONSTRATED A FAVORABLE SAFETY AND TOLERABILITY PROFILE. ALL SUBJECTS IN STUDY RECEIVED 100 MG OF RILUZOLE PER DAY.MEDICINOVA INC - ALL TREATMENT-RELATED ADVERSE EVENTS (TRAES) WERE MILD TO MODERATE IN INTENSITY & NO SEVERE OR LIFE-THREATENING TRAES WERE REPORTED.  Full Article

Medicinova announces positive top-line results from the Sprint-MS Phase 2B trial of MN-166 (ibudilast)
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Medicinova Inc ::Medicinova announces positive top-line results from the Sprint-MS phase 2B trial of MN-166 (ibudilast) in progressive MS: achieved both primary endpoints including a significant reduction in whole brain atrophy and safety and tolerability.Medicinova Inc - ‍MN-166 demonstrated a statistically significant reduction in rate of progression of whole brain atrophy compared to placebo in study​.Medicinova Inc - ‍MN-166 was safe and well tolerated in study​.  Full Article